Search results
Apr 7, 1999 · Revolutionized the field of psychiatry and established the foundation for psychopharmacology. A pioneer in psychiatric clinical investigation. Dr. Heinz Lehmann has helped shape modern psychiatric care by recognizing the impact of two different drugs on the treatment of mental disorders.
Heinz Edgar Lehmann OC FRSC (July 17, 1911 – April 7, 1999) was a German-born Canadian psychiatrist best known for his use of chlorpromazine for the treatment of schizophrenia in 1950s and "truly the father of modern psychopharmacology."
Dr. Heinz Lehmann has helped shape modern psychiatric care by recognizing the impact of two different drugs on the treatment of mental disorders. In 1952, Lehmann found that the drug chlorpromazine effectively treated the various states of psychotic patients.
The founding president of the Quebec Psychopharmacological Research Association, he served as president of the American College of Neuropsychopharmacology, president of the Collegium Internationale Neuro-Psychopharmacologicum, and chairman of the McGill Department of Psychiatry.
- John M. Oldham
- 2001
Feb 29, 2024 · This spirit has its roots in the first forays into psychopharmacology conducted by the visionary pioneer, Dr. Heinz Edgar Lehmann. Dr. Lehmann, was born in Berlin in 1911, fled Nazi Germany in 1937, eventually making ground-breaking contributions to mental health in Canada.
On April 7, 1999, Canada lost one of its pioneers in psychiatry, Heinz Lehmann. Born in Berlin on July 17, 1911, Lehmann arrived in this country in 1937, and began practising psychiatry in a place where few chose to work: Verdun Protestant Hospital, now called the Douglas Hospital.
People also ask
How did Heinz Lehmann shape modern psychiatric care?
Who was Heinz Lehmann?
What is Dr Lehmann's approach to psychiatric care?
Why is Dr Lehmann important?
Jan 23, 2017 · In the spring of 1953 at the Verdun Protestant Hospital in Montreal, the psychiatrist Heinz Lehmann initiated the first trial of chlorpromazine in North America, treating “psychomotor excitement” in patients with diagnoses ranging from manic depression to schizophrenia. 1,2 Within weeks, the drug proved a remarkable success: patients ...
